The Brazil CDMO market was valued at USD 10.64 Billion in 2025 driven by well-established pharmaceutical manufacturing base, bolstered by skilled professionals and regulatory alignment with international standards, particularly ANVISA's growing collaboration with global health agencies across the region. It is expected to grow at a CAGR of 8.80% during the forecast period of 2026-2035 and attain a market value of USD 24.73 Billion by 2035.
Base Year
Historical Period
Forecast Period
The growing demand for biosimilars and biologics is driving expansion of Brazil’s CDMO capabilities and investments.
The increasing pharmaceutical R&D outsourcing supports the market growth, enhancing specialized contract development services.
Major growth drivers include regulatory reforms and improved infrastructure, intended to boost Brazil’s attractiveness for local and international CDMO partnerships and projects.
Compound Annual Growth Rate
8.8%
Value in USD Billion
2026-2035
*this image is indicative*
Contract development and manufacturing organizations (CDMOs) in Brazil play a pivotal role in advancing the country's pharmaceutical sector by offering end-to-end services, from drug development to commercial-scale manufacturing. They support both domestic and international companies by providing cost-effective, scalable solutions tailored to local regulatory requirements. With increasing investments in biologics, biosimilars, and gene therapies, Brazilian CDMOs are fostering innovation and accelerating market entry. Their expanding capabilities, especially in cell and gene therapy manufacturing, are transforming Brazil into a strategic hub for biopharmaceutical production across Latin America, enhancing self-sufficiency and global competitiveness.
Advancements in Cell Therapy Manufacturing Driving Market Development
The rising demand for advanced cell and gene therapies alongside Brazil’s push for affordable treatment access is shaping the CDMO market. For instance, in March 2024, a partnership was announced between Fiocruz and the U.S.-based nonprofit Caring Cross to locally develop and manufacture CAR-T cell and stem cell gene therapies for oncology and infectious diseases. By enabling technology transfer and reducing production costs, this initiative is set to expand Brazil’s CDMO capabilities, foster biologics innovation, and boost market growth across Latin America in the forecast period.
Growing localization efforts and innovation-driven investments are reshaping Brazil’s CDMO market landscape significantly.
Expansion in End-to-End Biologics CDMO Capabilities to Boost Brazil CDMO Market Demand
The market is witnessing strong infrastructure growth driven by domestic investment in biologics manufacturing. For instance, in September 2022, Biotimize announced plans to establish Brazil’s first end-to-end biological CDMO facility in Piracicaba, São Paulo, after securing USD 30 million in Series A funding. The facility will focus on producing monoclonal antibodies, recombinant proteins, and biosimilars using mammalian cell platforms. This development is poised to enhance Brazil’s biologics manufacturing capacity, attract regional biopharma clients, and support the country’s ambition to become a biologics production hub.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Service Type
Market Breakup by Therapeutic Area
Market Breakup by End User
Oncological Disease to Lead the Market Share by Therapeutic Area
Oncological disease is likely to hold the largest market share in the market due to the rising prevalence of cancer and growing demand for complex biologics like monoclonal antibodies and CAR-T therapies. The country’s focus on expanding access to advanced cancer treatments through public-private partnerships and local manufacturing initiatives further strengthens this segment. Additionally, ongoing innovation in oncology therapeutics requires specialized development and manufacturing expertise, positioning CDMOs as key players in meeting this demand efficiently and at a scale.
The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Founded in 1972 and headquartered in São Paulo, Brazil, Eurofarma is a leading pharmaceutical company and Contract Development and Manufacturing Organization (CDMO) in Latin America. It offers a diverse portfolio spanning active pharmaceutical ingredients (APIs), generics, and branded medicines. Eurofarma provides end-to-end CDMO services, including formulation development, manufacturing, and packaging, supporting both domestic and international clients with high-quality standards and regulatory compliance.
Established in 2013 and based in São Paulo, Brazil, Bionovis is a prominent biopharmaceutical company focused on biotechnological CDMO services. The company specialises in developing and manufacturing biosimilars and innovative biologics. With state-of-the-art facilities, Bionovis offers integrated contract development and manufacturing services, supporting clients from early-stage development through commercial production, contributing significantly to Brazil’s biopharma and CDMO sectors.
Founded in 1966 and headquartered in São Paulo, Brazil, Ache Laboratorios Farmaceuticos is a well-established pharmaceutical company with expanding CDMO capabilities. The company’s portfolio includes generics, branded medicines, and active pharmaceutical ingredients. Ache provides comprehensive contract manufacturing and development services, including solid, liquid, and semi-solid dosage forms, catering to domestic and Latin American markets with a focus on quality, innovation, and regulatory adherence.
AGC Pharma Chemicals Inc., a subsidiary of the global AGC Group, operates in Brazil as a key player in CDMO services. Founded globally in 1997 and active in Brazil since the 2000s, AGC specialises in high-purity pharmaceutical chemicals and intermediates. The company offers customised contract manufacturing solutions, including synthesis and scale-up of APIs and intermediates, leveraging advanced technologies to meet the rigorous standards of pharmaceutical clients worldwide.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Recipharm AB, Boehringer Ingelheim, Patheon Pharma Services (Thermo Fisher Scientific Inc.), Pfizer Inc., AVANTI PESQUISA CLINICA LTD, Lonza Group, WuXi AppTec, B. Braun SE, and WuXi Biologics.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Service Type |
|
| Breakup by Therapeutic Area |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share